Reports Q2 revenue $102.7M, consensus $85.58M. Cash, cash equivalents, marketable securities and restricted cash was $135.5M as of June 30. “Crossing the $100M revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx (WGS), putting us on a path for more growth at scale and enabling us to reach more patients while reducing unnecessary spend across the global healthcare system,” said Katherine Stueland, CEO. “Our strong Q2 performance was driven by our core business, underscoring its strength and resilience. These results, coupled with the ever-expanding opportunities ahead, including general pediatrics, demonstrate that we’re just beginning to deliver on the promise of how our technology can fundamentally change the way genomics can inform healthcare, shifting from reactive to proactive care.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx Holdings: Strong Market Position and Growth Potential in Rare Disease Testing
- GeneDx initiated with an Overweight at Piper Sandler
- GeneDx price target raised to $115 from $88 at Guggenheim
- GeneDx announces SeqFirst study data on rapid genomic testing in pediatrics
- GeneDx says AAP recommends exome, genome sequencing as tests for children